Compare FLY & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLY | INDV |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | 1409 | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 4.7B |
| IPO Year | N/A | 2014 |
| Metric | FLY | INDV |
|---|---|---|
| Price | $39.93 | $37.97 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $38.88 | N/A |
| AVG Volume (30 Days) | ★ 5.5M | 1.9M |
| Earning Date | 05-04-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $174.79 | N/A |
| Revenue Next Year | $66.73 | N/A |
| P/E Ratio | ★ N/A | $56.35 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $16.00 | $11.07 |
| 52 Week High | $55.00 | $41.00 |
| Indicator | FLY | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 62.08 |
| Support Level | $18.95 | $29.71 |
| Resistance Level | $48.28 | N/A |
| Average True Range (ATR) | 3.79 | 1.54 |
| MACD | -0.05 | 0.27 |
| Stochastic Oscillator | 89.20 | 63.98 |
Firefly Aerospace Inc is a space and defense technology company with an established track record of success providing comprehensive mission solutions to national security, government, and commercial customers. The company develops and provides space and defense technologies, including launch vehicles and spacecraft systems, supporting launch, transit, and in-orbit operations for government, commercial, and national security customers. It has only one operating segment. The majority of the company's revenue is derived from Spacecraft Solutions.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).